



Company Announcement no. 25/2010

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, November 25, 2010

LifeCycle Pharma A/S - Major Shareholder Announcement

LifeCycle Pharma A/S (OMX: LCP) has received a major shareholder notice, that Novo A/S has increased its holdings of shares/voting rights in LifeCycle Pharma A/S from 13,404,663 shares/voting rights to 120,184,740 shares/voting rights, corresponding to an increase from 23.7 % of the total number of shares/voting rights in LifeCycle Pharma A/S to 26.6 % of the total number of shares/voting rights in LifeCycle Pharma A/S.

For more information, please contact:

LifeCycle Pharma A/S

William J. Polvino, President and CEO
Mobile: +1 917 647 9107
Email: WJP@lcpharma.com

Johnny Stilou, CFO
Mobile: +45 20 55 38 52
Email: JST@lcpharma.com

Forward-looking statement disclaimer

This press release contains certain forward-looking statements, including statements about the Company's business and its shares. Such forward-looking statements are based on data, assumptions and estimates that the Company considers to be reasonable. They are subject to numerous risks and uncertainties, including matters not yet known to the Company or not currently considered material by the Company, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in forward-looking statements include, among others, market conditions and the price of the Company's shares, completion of and the actual outcome of the Company's ongoing Phase III clinical studies of LCP-Tacro™, as well as changes in pharmaceutical industry regulation and, in particular, regulatory approval of pharmaceutical drugs, as well as the other risk factors the Company has included in its public disclosures.